This study is testing an experimental drug called DM001 for people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers. DM001 is a bispecific antibody-drug conjugate (ADC), meaning it's designed to target two specific markers (TROP2 and EGFR) on cancer cells. The main goals are to find out how safe DM001 is, what dose is best tolerated, and if it shows any early signs of working. You might be able to join if your cancer has progressed after standard treatments or if you can't tolerate those treatments. The study is currently unclear on its recruitment status and plans to enroll 128 participants.

Study design

This is a Phase 1, open-label study, meaning both you and the study team will know you are receiving DM001. It aims to enroll 128 participants.

What's involved

You would have up to 17 visits over the course of the study, starting with a 4-week screening period. Treatment cycles are every three weeks, with more frequent visits early on.

Compensation

Not stated in the trial record.

Follow-up

After your last dose of DM001, you will have an End of Treatment visit about 21 days later, followed by a final follow-up visit about 30 days after that.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.